Momentive Software Cebu Office

https://efim.org › node
Human medicines European public assessment report EPAR Rinvoq upadacitinib Date of authorisation 16 12 2019 Revision

https://www.ema.europa.eu › en › documents › assessment...
The applicant AbbVie Deutschland GmbH Co KG submitted on 18 December 2018 an application for marketing authorisation to

https://efim.org › node
Human medicines European public assessment report EPAR Rinvoq upadacitinib Arthritis Rheumatoid Date of

https://www.ema.europa.eu › en › documents › overview › ...
How does Rinvoq work Upadacitinib the active substance in Rinvoq is an immunosuppressant a medicine that reduces the

https://www.ema.europa.eu › en › documents › variation-report
C I 6 Extension of indication Extension of indication to include the treatment of active ankylosing spondylitis in adult patients for

https://data.europa.eu › data › datasets › epar-human-medicines
EPARs are full scientific assessment reports of medicines authorised at a European Union level You can find information including a

https://ec.europa.eu › health › documents › community...
The safety and efficacy of RINVOQ in children and adolescents with rheumatoid arthritis psoriatic arthritis and ankylosing spondylitis

https://pharmacafennica.fi › spc
RINVOQ on tarkoitettu keskivaikean tai vaikean atooppisen ihottuman hoitoon aikuisille ja v hint n 12 vuotiaille nuorille joille

https://www.ema.europa.eu › en › documents › procedural...
Extension of indication to include the treatment of giant cell arteritis GCA in adult patients for RINVOQ based on final results from